Since its founding 20 years ago, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Alnylam is headquartered in Cambridge, MA. For more information, visit www.alnylam.com.
